See more : Basetrophy Group Holdings Limited (8460.HK) Income Statement Analysis – Financial Results
Complete financial analysis of GH Research PLC (GHRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GH Research PLC, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Made.com Group Plc (MADE.L) Income Statement Analysis – Financial Results
- O Sorbet D’amour SA (MLOSA.PA) Income Statement Analysis – Financial Results
- Max Metal Corporation Public Company Limited (MAX.BK) Income Statement Analysis – Financial Results
- Global Partners LP (GLP) Income Statement Analysis – Financial Results
- Mistango River Resources Inc. (MIS.CN) Income Statement Analysis – Financial Results
GH Research PLC (GHRS)
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 315.00K | 47.00K | 19.00K | 0.00 | 0.00 |
| Gross Profit | -315.00K | -47.00K | -19.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.79M | 20.48M | 8.55M | 338.00K | 296.00K |
| General & Administrative | 11.30M | 10.07M | 6.55M | 108.00K | 14.00K |
| Selling & Marketing | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.12M | 10.07M | 6.55M | 108.00K | 14.00K |
| Other Expenses | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Cost & Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Interest Income | 1.89M | 858.00K | 9.00 | 0.00 | 0.00 |
| Interest Expense | 723.00K | 0.00 | 9.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 315.00K | 47.00K | 19.00K | 446.00K | 310.00K |
| EBITDA | -41.15M | -30.63M | -15.08M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -41.22M | -30.55M | -15.10M | -446.00K | -310.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.64M | 8.10M | 5.90M | 0.00 | 0.00 |
| Income Before Tax | -35.59M | -22.46M | -9.20M | -446.00K | -310.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.32M | 9.00K | -205.30K | -310.00 |
| Net Income | -35.59M | -7.14M | -9.21M | -446.00K | -310.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| EPS Diluted | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
| Weighted Avg Shares Out (Dil) | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided...
3 Fast-Growing Stocks Analysts See Doubling in Price
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than...
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided...
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief...
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Source: https://incomestatements.info
Category: Stock Reports